Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
The in vitro and in vivo toxicities and activities of MS-8209, a new hydrosoluble amphotericin B (deoxycholate-amphotericin B [D-AmB]; Fungizone) derivative, were studied. In vitro, MS-8209 was less toxic than AmB against renal tubular cells in primary culture and less active against Candida albicans and Cryptococcus neoformans. However, at 10-fold the AmB concentration, MS-8209 in vitro antifungal activity paralleled that of AmB. Fifty-percent lethal doses of MS-8209 and D-AmB in OF1 noninfected mice were 26 and 2.3 mg/kg, respectively. Therapeutic efficacy of MS-8209 was assessed in murine candidiasis, cryptococcosis, and aspergillosis. In each model of infection, we determined the maximum tolerated dosages of MS-8209 and D-AmB, i.e., the dosage inducing less than 15% mortality due to toxicity; the efficacies of MS-8209 and D-AmB at their respective maximum tolerated dosages were compared. In candidiasis, MS-8209 (15 mg/kg) significantly increased the survival time compared with D-AmB (0.5 mg/kg). Both compounds were equally effective at reducing CFU counts in the kidney. MS-8209 was the most effective agent for increasing the survival time in cryptococcal meningoencephalitis and for reducing CFU counts in spleen, brain, and lung during both cryptococcal pneumonia and meningoencephalitis. In aspergillosis, MS-8209 and D-AmB similarly prolonged the survival of treated mice compared with controls. These results show that when MS-8209 and D-AmB were used at the maximum tolerated dosage, MS-8209 was as effective as or more effective than D-AmB for the treatment of systemic mycoses. These findings warrant further experiments to study the pharmacokinetic properties and toxicity of MS-8209 under conditions of chronic administration.
Saint-Julien
L
L
Laboratoire d'Etude des Infections Expérimentales, Faculté X. Bichat, Chatou, France.
Joly
V
V
Seman
M
M
Carbon
C
C
Yeni
P
P
D000666:Amphotericin B / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D002478:Cells, Cultured; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology; D007674:Kidney Diseases / Q000188:drug therapy / Q000382:microbiology; D007687:Kidney Tubules, Proximal / Q000166:cytology / Q000187:drug effects; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D011817:Rabbits
C074660:MS 8209; D000666:Amphotericin B